BioCentury
ARTICLE | Financial News

Akeso raises $45M in series B

August 28, 2017 10:13 PM UTC

Akeso Biopharma Inc. (Zhongshan, China) raised RMB300 million ($45.2 million) in a series B round led by Shenzhen GTJA Investment Group. Existing investors Shenzhen Capital, Qianhai Parent Fund and Qianhai TRI Wise Capital participated.

In 2015, Akeso granted Merck & Co. Inc. (NYSE:MRK) rights to its preclinical immune checkpoint blocking antibody AK-107 for an undisclosed upfront payment and up to $200 million in milestones...

BCIQ Company Profiles

Akeso Inc.